Clinical Results of Stereotactic Body Radiotherapy for Stage I Small Cell Lung Cancer: A Single Institutional Experience

Shioyama, Yoshiyuki; Ohga, Shouichi; Yoshitake, Tsuyoshi; Nonoshita, Takeshi; Ohnishi, Kayoko; Terashima, Kotaro; Asai, Kaori; Nakamura, Katsumasa; Hayashi, Hideki; Honda, Hiroshi

doi:10.1016/j.ijrobp.2010.07.1228

Cited by 2 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, it has been reported that not only NSCLC but also small lung metastases and small-cell lung cancer can be successfully treated with stereotactic body radiotherapy (SBRT) [5, 6]. Since lung tumors can move due to respiration, cardiac motion, and aortic pulsation, managing tumor motion is very important for further refining the technique.…”

Section: Introductionmentioning

confidence: 99%

Percutaneous fiducial marker placement under CT fluoroscopic guidance for stereotactic body radiotherapy of the lung: an initial experience

Ohta

Iwata

Hashizume

et al. 2013

Journal of Radiation Research

View full text Add to dashboard Cite

The aim of this study is to describe our initial experience with the VISICOIL, which is the first percutaneous fiducial marker approved for stereotactic body radiotherapy in Japan, and to evaluate its technical and clinical efficacy, and safety. Eight patients underwent this procedure under CT fluoroscopic guidance. One patient had two tumors, so the total number of procedures was nine. We evaluated the technical and clinical success rates of the procedure and the frequencies of complications. Technical success was defined as when the fiducial marker could be placed at the target site, and clinical success was defined as when stereotactic body radiotherapy could be performed without the marker dropping out of position. The technical success rate was 78% (7/9). In one of the two failed cases, we aimed to place the marker inside the tumor, but misplaced it beside the tumor. In the other failed case, we successfully placed the marker beside the tumor as planned; however, the marker migrated to near the pleura after the patient stopped holding their breath. None of the markers dropped out of place, so the clinical success rate was 100% (9/9). The complication rates were as follows: pneumothorax: 56% (5/9), pneumothorax necessitating chest tube placement: 44% (4/9), focal intrapulmonary hemorrhaging: 67% (6/9), hemoptysis: 11% (1/9), mild hemothorax 11% (1/9), air embolism 0% (0/9), and death 0% (0/9). In conclusion, this new percutaneous fiducial marker appears to be useful for stereotactic body radiotherapy due to its good stability.

show abstract

Section: Introductionmentioning

confidence: 99%

Percutaneous fiducial marker placement under CT fluoroscopic guidance for stereotactic body radiotherapy of the lung: an initial experience

Ohta

Iwata

Hashizume

et al. 2013

Journal of Radiation Research

View full text Add to dashboard Cite

show abstract

“…The 3-year local control and survival rates were 100% and 72%, respectively. SBRT-associated toxicity of grade 2 or more was not observed (12). Videtic et al (13) reported 6 cases with inoperable stage I SCLC whose primary tumors were managed with SBRT.…”

Section: A B C D Discussionmentioning

confidence: 95%

“…Conversely, the minimum biological effective dose (BED) delivered by SBRT >100 Gy 10 (11). Compared with NSCLC, few studies have investigated SBRT in SCLC (12)(13)(14). One reason is that ~5% of SCLCs are stage I (15).…”

Section: A B C D Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Stereotactic body radiation therapy for the treatment of a post-chemotherapy remnant lung mass in extensive-stage small-cell lung cancer: A case report

Yeo

Kim

2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

Clinical Results of Stereotactic Body Radiotherapy for Stage I Small Cell Lung Cancer: A Single Institutional Experience

Cited by 2 publications

References 15 publications

Percutaneous fiducial marker placement under CT fluoroscopic guidance for stereotactic body radiotherapy of the lung: an initial experience

Percutaneous fiducial marker placement under CT fluoroscopic guidance for stereotactic body radiotherapy of the lung: an initial experience

Stereotactic body radiation therapy for the treatment of a post-chemotherapy remnant lung mass in extensive-stage small-cell lung cancer: A case report

Contact Info

Product

Resources

About